Raloxifene

ID: raloxifene

Aliases: Evista, raloxifene hydrochloride

Type: compound

Route/form: oral

Status: approved

Evidence level: approved / labelled

Best data tier: approved label + human controlled/review

Support scope: human

Source types: human_trial, label, systematic_review

Linked sources: 3

Broad outcomes: Hormones / fertility / sexual health

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• estrogen receptor modulator
• ER agonist in bone
• ER antagonist in breast tissue

Optimization domains

• SERM
• osteoporosis
• breast cancer risk
• gynecomastia
• endocrine

Research basis

• Optimization angle: raloxifene is mainly interesting for breast-tissue ER antagonism and gynecomastia discussions, not for testosterone recovery.
• Bone ER agonism and male antiestrogen physiology data show why SERMs are tissue-selective rather than simple estrogen blockers.
• It is a useful comparison point for tamoxifen when the question is breast tissue versus HPTA stimulation.

Limits, risks, and missing evidence

• It is not a PCT or HPTA-stimulation tool in the way clomiphene/enclomiphene are discussed.
• VTE and stroke warnings dominate risk framing; gynecomastia use is off-label with limited evidence.
• Endocrine marker changes in small male studies do not establish a performance-enhancement role.

Risk flags

• prescription only
• thrombotic risk
• off label male context
• stroke warning

Linked papers, labels, and reviews

1. DailyMed label: EVISTA raloxifene hydrochloride tablet
   label / dailymed_raloxifene_label
   Approved SERM label for postmenopausal osteoporosis and invasive breast cancer risk reduction.
2. Gynecomastia: a systematic review of pharmacological treatments
   systematic_review / pubmed_gynecomastia_pharm_review_2022
   Reviews SERM, aromatase inhibitor, and androgen pharmacologic approaches for gynecomastia.
3. Antiestrogenic properties of raloxifene
   human_trial / pubmed_raloxifene_tamoxifen_male_antiestr_1995
   Healthy-male volunteer study comparing raloxifene/tamoxifen endocrine responses to estrogen challenge; useful SERM mechanism anchor.